Effect of rivaroxaban in radial artery thrombosis

Efficacy and safety of rivaroxaban versus enoxaparin on treatment of radial artery thrombosis after coronary arteries angiography

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200111046084N1

Enrollment

Registered

2020-05-15

Start date

2018-09-23

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Radial artery thrombosis. Embolism and thrombosis of arteries of the upper extremities

Interventions

Intervention 1: Intervention group: Rivaroxaban 20 mg oral tablet , patents will receive rivaroxaban 20 mg daily for 4 weeks after diagnosis of radial artery thrombosis. Intervention 2: Control group:

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Provision of signed and dated informed consent form All the patients that diagnosed with radial artery thrombosis after coronary angiography Men and Women being at the age of 18 years old or over

Exclusion criteria

Exclusion criteria: Patients undergoing percutaneous coronary intervention A condition associated with a high risk of bleeding Severe renal dysfunction (creatinine clearance <30 mL/min) Being allergic to rivaroxaban/enoxaparin

Design outcomes

Primary

Measure	Time frame
Radial artery recanalization. Timepoint: 4 weeks after start of treatment with rivaroxaban or enoxaparin. Method of measurement: Doppler Ultrasound.	—

Secondary

Measure	Time frame
Bleeding. Timepoint: During 4 weeks of treatment with rivaroxaban or enoxaparin. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactParham Sadeghipour

Rajaie Cardiovascular Medical and Research Center

psadeghipour@rhc.ac.ir+98 21 2392 2092

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026